Gilead Sciences (GILD) Reports POC Data for GS-0976 in Nonalcoholic Steatohepatitis at The International Liver Congress 2017
Tweet Send to a Friend
Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from an open-label, proof-of-concept study evaluating GS-0976, an investigational inhibitor of Acetyl-CoA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
